Chasing the cabotegravir tail: implications for prevention
Lancet HIV
.
2020 Jul;7(7):e451-e453.
doi: 10.1016/S2352-3018(20)30165-X.
Epub 2020 Jun 1.
Author
Kimberly K Scarsi
1
Affiliation
1
Antiviral Pharmacology Laboratory, College of Pharmacy, and Division of Infectious Diseases, College of Medicine, University of Nebraska Medical Center, Omaha, NE 68198, USA. Electronic address: kim.scarsi@unmc.edu.
PMID:
32497490
DOI:
10.1016/S2352-3018(20)30165-X
No abstract available
Publication types
Comment
MeSH terms
Anti-HIV Agents*
HIV Infections*
Humans
Pyridones
Substances
Anti-HIV Agents
Pyridones
cabotegravir
Associated data
ClinicalTrials.gov/NCT02720094
ClinicalTrials.gov/NCT03164564